Yi C Zhu

20130121221, May 16, 2013

Sep 12, 2012

13/612730

Sandip HomChaudhuri - Santa Clara CA, US
Vinod Nagarajan - Saratoga CA, US
Anand Rajagopalan - Saratoga CA, US
Arunkumar Jayaraman - San Jose CA, US
Yi Zhu - San Jose CA, US
Zhanfeng Jia - Belmont CA, US

Qualcomm Atheros, Inc. - San Jose CA

H04W 52/02

370311

A method of saving power in a wireless network can include determining a plurality of stations associated with an AP. The AP can create station groups using group selection logic. Notably, the group selection logic is transparent to the plurality of stations. A plurality of TIMs can then be sent, each TIM allowing only one station group access to a channel during a predetermined time interval, such as a beacon interval. In another method, a station can determine its sleep duration based on at least one of first information from the TIM to generate random sleep duration, second information regarding previous operation of the station, and third information regarding a status of the station. The first, second, and third information can include the number of stations associated with the AP and having buffered data based on the TIM, historical collisions, and power status.

20140036892, Feb 6, 2014

Jul 31, 2012

13/563614

Yi ZHU - San Jose CA, US

Qualcomm Atheros, Inc. - San Joe CA

H04W 84/12

370338

Systems and methods are disclosed to provide a bridge for a wireless distribution system compatible with legacy equipment, including the use of a bridge device having two WLAN modules, with the first WLAN module associating with one or more stations and the second WLAN module configured to associating with a legacy access point. Frames received by the first WLAN module are forwarded to the second WLAN module for transmission and frames received by the second WLAN module are forwarded to the first WLAN module for transmission on the basis of address information in the frames.

20140037091, Feb 6, 2014

Aug 1, 2012

13/563977

Yi ZHU - San Jose CA, US
Anand RAJAGOPALAN - Saratoga CA, US
Matthew Daniel SMITH - San Jose CA, US
Vinod NAGARAJAN - Saratoga CA, US

QUALCOMM ATHEROS, INC. - San Jose CA

H04L 9/00

380255

Systems and methods are disclosed to improve performance of a communications device receiving encrypted communications from multiple sources. The communications device is configured to increase the amount of decryption performed using a hardware-based process as compared to a software-based process by reprogramming the hardware to store a shared security key corresponding to a frame received from a source, allowing the hardware-based process to decrypt subsequent frames from that source.

20200030323, Jan 30, 2020

Sep 26, 2019

16/584638

- Novato CA, US
- Rochester MN, US
- Brisbane CA, US
Nathaniel David - Brisbane CA, US
James L. Kirkland - Rochester MN, US
Tamar Tchkonia - Rochester MN, US
Yi Zhu - Rochester MN, US
Darren J. Baker - Rochester MN, US
Jan M.A. van Deursen - Rochester MN, US

A61K 31/496
A61P 11/00
A61P 9/10
A61P 27/02
A61K 31/428
A61K 31/495
A61K 31/5377
A61K 31/404
A61K 31/4375
A61K 45/06
A61K 31/4178
A61K 31/728
C12N 5/00
A61K 47/36
A61K 9/00

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

20190343832, Nov 14, 2019

Jul 10, 2019

16/508119

- Brisbane CA, US
- Novato CA, US
- Rochester MN, US
- Baltimore MD, US
Nathaniel David - Brisbane CA, US
Alain Philippe Vasserot - Carlsbad CA, US
James L. Kirkland - Rochester MN, US
Tamar Tchkonia - Rochester MN, US
Jennifer Elisseeff - Baltimore MD, US
Chaekyu Kim - Pikesville MD, US
Okhee Jeon - Baltimore MD, US
Yi Zhu - Rochester MN, US

A61K 31/496
A61K 9/00
A61P 9/10
A61K 47/36
A61P 11/00
A61P 27/02
C12N 5/00
A61K 31/728
A61K 31/4178
A61K 45/06
A61K 31/4375
A61K 31/404
A61K 31/5377
A61K 31/495
A61K 31/428

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

20190269675, Sep 5, 2019

May 3, 2019

16/403389

- Novato CA, US
- Brisbane CA, US
- Rochester MN, US
Nathaniel David - Brisbane CA, US
James L. Kirkland - Rochester MN, US
Tamar Tchkonia - Rochester MN, US
Yi Zhu - Rochester MN, US

A61K 31/496
A61K 9/00
A61P 9/10
A61K 47/36
A61P 11/00
A61P 27/02
C12N 5/00
A61K 31/728
A61K 31/4178
A61K 45/06
A61K 31/4375
A61K 31/404
A61K 31/5377
A61K 31/495
A61K 31/428

This invention establishes a new paradigm for treatment of Parkinson's disease (PD) by eliminating senescent cells that reside in or around the site of the disease pathophysiology. Exposure of test subjects to the herbicide paraquat (PQ) increases the risk for developing Parkinson's disease. The data in this disclosure show that PQ induces a senescence arrest and SASP in astrocytes, in culture and in vivo in mice, and senescent cell markers were present in astrocytes in midbrain tissue from PD patients. In a transgenic mouse model, senescent cell ablation protected against PQ-induced PD-like neuropathology. Removal of senescent cells from affected sites using small molecule agents that specifically target senescent cells can help prevent or ameliorate signs and symptoms of the disease.

20190180326, Jun 13, 2019

Feb 19, 2019

16/279557

- Mountain View CA, US
Eric L. LORENZO - Mountain View CA, US
Yi ZHU - Mountain View CA, US
Amin Charaniya - Mountain View CA, US
Gaurav Ravindra BHAYA - Mountain View CA, US
Gaurav Ravindra BHAYA - Sunnyvale CA, US

Google LLC - Mountain View CA

G06Q 30/02

Methods, systems, and apparatus include computer programs encoded on a computer-readable storage medium, including a method for providing content. A request for content is received from a user device. A content item is identified for delivery to the user device responsive to the request. A location of the user device is determined. A threshold distance is determined that a user is likely willing to travel when visiting a physical location associated with the content item or content sponsor. A bounding region associated with the location of the user device is identified. Location extensions are identified that are associated with the content item. A determination is made when one of the location extensions is included in the bounding region and when a distance between the location extension and a current location of the user is less than the determined threshold distance. The content item is augmented with the one location extension.

20190022090, Jan 24, 2019

Aug 3, 2018

16/054667

- Brisbane CA, US
- Novato CA, US
- Rochester MN, US
Nathaniel David - Brisbane CA, US
Alain Philippe Vasserot - Carlsbad CA, US
James L. Kirkland - Rochester MN, US
Tamar Tchkonia - Rochester MN, US
Yi Zhu - Rochester MN, US
Darren J. Baker - Rochester MN, US
Bennett G. Childs - Rochester MN, US
Jan M.A. van Deursen - Rochester MN, US

A61K 31/496
A61K 9/00
A61K 31/428
A61K 47/36
C12N 5/00
A61K 31/728
A61K 31/4178
A61K 45/06
A61K 31/4375
A61K 31/404
A61K 31/5377
A61K 31/495

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.